| Title | Description | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Active Ingredients |
|
||||||||
| Dosage Form | TABLET, FILM COATED | ||||||||
| Packaging | 180 TABLET, FILM COATED in 1 BOTTLE (42385-929-18), 30 TABLET, FILM COATED in 1 BOTTLE (42385-929-30), 30 TABLET, FILM COATED in 1 BOTTLE (42385-929-31), 180 TABLET, FILM COATED in 1 BOTTLE (42385-929-82), 90 TABLET, FILM COATED in 1 BOTTLE (42385-929-90), 90 TABLET, FILM COATED in 1 BOTTLE (42385-929-91), | ||||||||
| Pharm Type | Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleosides [CS] |